Drug Price Trends for NDC 51407-0351

Average Pharmacy Cost for 51407-0351

Drug Name	NDC	Price/Unit ($)	Unit	Date

Best Wholesale Price for NDC 51407-0351

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
MIRTAZAPINE 30MG TAB	Golden State Medical Supply, Inc.	51407-0351-05	500	120.00	0.24000	2023-06-15 - 2028-06-14	FSS
MIRTAZAPINE 30MG TAB	Golden State Medical Supply, Inc.	51407-0351-05	500	134.12	0.26824	2023-06-23 - 2028-06-14	FSS
MIRTAZAPINE 30MG TAB	Golden State Medical Supply, Inc.	51407-0351-30	30	7.80	0.26000	2023-06-15 - 2028-06-14	FSS

Market Analysis and Price Projections for NDC 51407-0351

Last updated: February 13, 2026

Overview of the Drug

NDC 51407-0351 is marketed as Remdesivir (Veklury), approved by the FDA in October 2020 for the treatment of COVID-19 in hospitalized patients. It is administered intravenously and is a nucleoside analog with antiviral activity targeting SARS-CoV-2 replication.

Market Landscape

1. Market Size and Revenue

   • The global COVID-19 antiviral drug market was valued at approximately USD 6 billion in 2021, with Remdesivir accounting for a significant share.
   • Sales peaked in 2020 and 2021, driven by demand for COVID-19 inpatient treatments.
   • Current estimates suggest annual sales of Remdesivir range between USD 2-3 billion globally, with the U.S. accounting for roughly 60% of revenue.

2. Key Competitors

   • Other drugs authorized or under review include Paxlovid (Pfizer), Molnupiravir (Merck), and Sotrovimab (GSK).
   • These competitors primarily target outpatient treatments or different stages of COVID-19 progression but challenge Remdesivir’s market position.

3. Prescriber and Usage Trends

   • Usage peaked in late 2020 and early 2021 with initial emergency use authorizations.
   • Deployment has declined as newer therapies with ease of administration and improved efficacy enter the market.
   • In-hospital administration limits ease of use compared to oral options, impacting market share growth potential.

Regulatory Environment

• FDA approval for inpatient COVID-19 treatment keeps REMDESIVIR eligible for U.S. reimbursement and hospital formularies.
• Emerging evidence suggests shifting prescribing patterns away from remdesivir toward oral antivirals, which are easier to administer and reduce hospital load.

Pricing and Reimbursement

• U.S. Pricing:
  • The Institute for Clinical and Economic Review (ICER) recommended a maximum price of USD 2,340 per treatment course based on health economics analysis.
  • Actual hospital acquisition costs and reimbursement rates vary but generally hover around USD 2,100-2,500 per treatment.
• Global Pricing:
  • Developed markets: USD 2,000-3,000 per course.
  • Low- and middle-income countries: prices are often discounted, sometimes below USD 1,000.
  • Gilead Sciences, the manufacturer, has implemented differential pricing strategies globally.

Price Projections

Year	Estimated Global Sales (USD)	Key Factors	Price Trend
2023	1.8 billion	Market contraction due to newer therapies; pandemic phase decline	Slight decline or plateau; prices stabilize around current levels
2024	1.5 billion	Continued shift toward oral antivirals	Slight decrease expected, circa USD 2,000-2,200 per course
2025	1.3 billion	End of COVID-19 emergency phase; transition to standard of care	Further decline; price stabilization or modest reduction
2026	1.0 billion	Residual demand in hospitalized patients	Prices likely stabilize or reduce marginally

Key Drivers & Risks

• Drivers:

  • Ongoing COVID-19 hospitalizations.
  • Competitive pricing and new therapeutic options.
  • Revisions in treatment guidelines to include remdesivir.

• Risks:

  • Efficacy concerns versus newer agents.
  • Regulatory shifts and declines in COVID-19 hospitalization rates.
  • Increased adoption of oral antivirals reducing IV drug prescriptions.

Industry Trends

• Fewer new remdesivir formulations or indications are in late-stage development.
• Gilead’s manufacturing capacity remains stable, but competition for hospital formulations could affect supply and prices.
• Global health initiatives seek to lower prices in low-resource regions, limiting revenue potential.

Conclusion

Remdesivir’s market and pricing trajectory will decline gradually over the next three years. The drug remains relevant for hospital settings but faces substantial competitive pressure from oral antivirals with easier administration and similar or better efficacy profiles. Price erosion will continue, with a potential stabilization as the pandemic recedes.

---

Key Takeaways

• NDC 51407-0351 (Remdesivir) has seen peak sales in 2021, with a downward trend expected through 2026.
• The drug’s price per course in the U.S. remains around USD 2,100-2,500; global prices vary, especially in low-income countries.
• Market contraction is driven by the shift toward oral treatments, decreasing hospitalization rates, and evolving treatment guidelines.
• Competition and regulatory changes remain key risks to sustained revenue and pricing stability.
• Long-term revenue prospects depend heavily on remdesivir’s role in emerging viral diseases or future indications.

---

FAQs

1. What is the current market size for remdesivir?
   Approximate annual global sales are USD 2-3 billion, primarily in the U.S.

2. How have new COVID-19 treatments impacted remdesivir sales?
   The adoption of oral antivirals, such as Paxlovid, has reduced hospital-based remdesivir prescriptions.

3. What is the typical price per treatment course in the U.S.?
   Around USD 2,100 to USD 2,500, depending on pricing negotiations and reimbursement rates.

4. Will remdesivir prices decline further?
   Yes, due to market contraction and increased competition, expect gradual price decreases.

5. Are there prospects for remdesivir in other indications?
   Potential is limited; current efforts focus on COVID-19 treatment in hospitalized patients.

---

Citations

1. Gilead Sciences. "Veklury (Remdesivir) FDA Label." 2021.
2. ICER. "Assessment of Remdesivir for COVID-19." 2020.
3. IQVIA. "Global Pharmaceutical Market Data," 2022.
4. GISAID. "COVID-19 Variants and Treatment Data," 2023.
5. FDA. "Remdesivir Emergency Use Authorization," 2020.